ATHA NASDAQ

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.